$599

Survo Adcom % > Zero?; ADA 2026 Key Press Releases (June 7)

On the third day of the ADA 2026 conference, four cardiometabolic-related news items have been observed from Boehringer Ingelheim, Novo Nordisk, Lilly, and Insulet/EOFlow. Below, FENIX provides context and analysis for the respective news items, including the speculative potential for a 2-day EMDAC featuring survo + reta (spoiler alert: it’s not a 0% chance).

This content is for Read Less members only.
Already a member? Log in here